E-mail

E-mail a Wiley Online Library Link

Hideyuki Akaza, Shiro Hinotsu, Michiyuki Usami, Yoichi Arai, Hiroshi Kanetake, Seiji Naito and Yoshihiko Hirao Combined androgen blockade with bicalutamide for advanced prostate cancer Cancer 115

Version of Record online: 17 JUN 2009 | DOI: 10.1002/cncr.24395

The long-term follow-up of the first double-blind, randomized study to directly compare combined androgen blockade (CAB) with bicalutamide 80 mg versus lutenizing hormone-releasing hormone agonist (LHRH-A) monotherapy demonstrated a significant overall survival advantage in favor of CAB. More patients who received CAB achieved a prostate-specific antigen (PSA) nadir of ≤1 ng/mL than patients who received LHRH-A monotherapy, and the patients who attained a PSA nadir of ≤1 ng/mL survived significantly longer than patients with PSA levels that remained above 1 ng/mL.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH